The study, led by Dagyeong Lee of Wonkwang University Sanbon Hospital and Sungkyunkwan University, together with biostatistician Kyungdo Han of Soongsil University and Dong Wook Shin of Samsung Medical Center, exploited a uniquely rich data infrastructure. South Korea’s National Health Insurance Service requires nearly all residents to attend periodic health screenings, during which body measurements and blood tests are collected, and the national cancer registry captures virtually every diagnosed malignancy in the country. By linking these systems, the team assembled a cohort of 635,867 adults who had been diagnosed with cancer and who had body composition data available around the time of diagnosis, allowing mortality outcomes to be tracked with unusual statistical power.

The technical backbone of the analysis was the appendicular skeletal muscle mass index, or ASMI, an estimate of the muscle contained in the arms and legs normalized to body size. Rather than relying on expensive imaging for every participant, the researchers used validated prediction equations that incorporate anthropometric measurements, serum creatinine levels and lifestyle factors, an approach previously validated in Korean adults. Patients falling in the lowest quartile of ASMI were classified as having low muscle mass, a definition aligned with the framework used by the Asian Working Group for Sarcopenia. Obesity was assessed two ways: a body mass index of 25 kilograms per square meter or higher, following Asia-Pacific criteria, and abdominal obesity defined as a waist circumference of at least 90 centimeters in men and 85 centimeters in women.

Using Cox proportional hazards regression, the team calculated adjusted hazard ratios that accounted for a broad range of potential confounders, including age, sex, smoking status, alcohol consumption, physical activity, income, comorbid conditions and cancer characteristics. Compared with patients in the highest ASMI quartile, those with low muscle mass showed a 25 percent higher risk of all-cause mortality, a 21 percent higher risk of dying specifically from cancer, a 49 percent higher risk of cardiovascular death and a startling 126 percent higher risk of respiratory death. The dose-response pattern was consistent: the less muscle a patient carried, the greater the mortality risk across every category examined.

Perhaps the most provocative result concerned the interaction between muscle and fat. Obesity, which is often assumed to be uniformly harmful in cancer patients, was actually associated with modestly lower mortality than non-obese status in this cohort, echoing the so-called obesity paradox reported in several cancer populations. But when low muscle mass and obesity coexisted, the protective veneer vanished. Patients with both conditions had the highest risks of all, with a 22 percent elevation in all-cause mortality and a 22 percent elevation in cancer-specific mortality compared with their counterparts. In other words, carrying extra fat did not rescue patients who lacked muscle; it appeared to compound their vulnerability.

This combination, often called sarcopenic obesity, has been recognized as a distinct clinical entity by international consensus statements from ESPEN and EASO in Europe and by an Asia-Oceania consortium, but its prognostic weight has been difficult to quantify because most prior studies were small, single-center or limited to specific tumor types. Meta-analyses of sarcopenia in solid tumors, including work in pancreatic, esophageal, lung and breast cancers, have consistently flagged poor outcomes, yet the new study is among the first to dissect cause-specific mortality at nationwide scale. By separating deaths due to cancer, cardiovascular disease and respiratory disease, the researchers revealed that muscle depletion is not merely a marker of advanced malignancy but a systemic risk factor operating across multiple organ systems.

The biological explanations are plausible and varied. Skeletal muscle is not an inert reservoir of protein; it is a metabolically active tissue that regulates glucose disposal, secretes anti-inflammatory myokines during contraction and serves as the body’s main amino acid store during illness. Cancer cachexia, the syndrome of muscle wasting that accompanies many malignancies, disrupts mitochondrial dynamics and promotes inflammation within muscle fibers, and low muscle mass is closely associated with elevated inflammatory markers such as erythrocyte sedimentation rate and low albumin. Depleted muscle also alters the pharmacokinetics of chemotherapy, potentially increasing toxicity, and predicts postoperative complications including pulmonary failure after esophagectomy and poor long-term outcomes in rectal cancer.

The respiratory findings deserve particular attention. Sarcopenia affects the diaphragm and intercostal muscles, compromising ventilatory capacity and cough strength, which helps explain why patients with low muscle mass were more than twice as likely to die from respiratory causes. Studies of cancer cachexia in animal models have documented diaphragm and ventilatory dysfunction, and clinical work has linked low muscle mass to severe dysphagia, raising aspiration risk. Meanwhile, the cardiovascular signal aligns with a growing literature showing that cardiovascular disease is a leading cause of death among long-term cancer survivors, driven partly by shared risk factors and partly by cardiotoxic treatments such as anthracycline chemotherapy, whose effects may be amplified in patients with depleted physiological reserve.

The authors emphasize that the practical message is not simply to gain weight but to build and preserve muscle. Clinical guidelines from the American Cancer Society already recommend that survivors maintain healthy weight through nutrition and physical activity, and randomized trials of combined aerobic and resistance training, along with dietary interventions, have shown meaningful improvements in body composition and cardiometabolic risk in patients with cancer. What the new study adds is a rationale for making muscle mass itself a routine clinical measurement at diagnosis, rather than an afterthought. Because the ASMI estimate can be derived from simple measurements already collected in health screenings, the barrier to implementation is low, particularly in health systems with structured screening programs.

Limitations remain. The cohort was exclusively Korean, and muscle mass thresholds and obesity criteria differ across populations, so the absolute risks may not translate directly to other ethnic groups. The prediction equations used to estimate ASMI, while validated, are less precise than direct imaging with computed tomography or dual-energy X-ray absorptiometry, and residual confounding by cancer stage, treatment intensity and unmeasured lifestyle factors cannot be excluded. The observational design means causality cannot be proven. Still, with more than 635,000 patients and consistent, graded associations across every cause of death examined, the study makes a compelling case that the scale tells only half the story. For oncologists and survivors alike, the takeaway is increasingly clear: in the fight against cancer, muscle is not optional equipment, and protecting it may be one of the most actionable steps available for extending survival.

Subject of Research: The association of low muscle mass and obesity with cause-specific mortality in cancer patients

Article Title: Low muscle mass, obesity, and cause-specific mortality in cancer patients: a nationwide cohort study

Article References: Lee, D., Kim, B., Jung, K.-W., Nam, G. E., Rhee, S. Y., Kim, S., Chun, S., Cho, I. Y., Han, K., & Shin, D. W. (2026). Low muscle mass, obesity, and cause-specific mortality in cancer patients: a nationwide cohort study. Cancer Causes & Control, 37(10), Article 156. https://doi.org/10.1007/s10552-026-02244-y

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02244-y

Keywords: low muscle mass, sarcopenia, sarcopenic obesity, cancer mortality, obesity paradox, body composition, cancer survivors, cardiovascular mortality, respiratory mortality, nationwide cohort study, ASMI, cancer prognosis

The new LE8 score, introduced by the American Heart Association, refines previous cardiovascular health assessment algorithms by encompassing eight critical health behaviors and factors. This study set out to quantify the association between cardiovascular health levels as measured by the LE8 score and mortality risks, providing a nuanced understanding of survival outcomes in both cancer-affected populations and those cancer-free. Researchers meticulously applied Cox proportional hazards regression models and utilized restricted cubic spline analyses to dissect these relationships with statistical precision.

Among the 29,352 adults studied, only a minority—14.8%—achieved a high LE8 cardiovascular health score, whereas 20.3% registered low scores indicative of suboptimal cardiovascular wellness. This distribution highlights a widespread public health challenge and underscores the importance of cardiovascular health maintenance. The stratification of LE8 scores into low, moderate, and high categories enabled a clear demonstration of how cardiovascular health correlates with mortality risk gradients.

For adults without cancer, the calculated hazard ratios (HRs) delineated a protective effect associated with improved LE8 scores. Specifically, individuals with moderate LE8 scores exhibited a 29% reduction in all-cause mortality risk compared to those with low scores, while those with high scores experienced an astounding 54% reduction. These findings underscore the LE8 score’s robustness as a prognostic tool and its potential utility in primary prevention strategies targeting cardiovascular events and overall survival enhancement.

When focusing on cardiovascular disease (CVD) mortality, the protective association strengthened further. Moderate LE8 scores correlated with a 42% risk reduction, and high scores nearly tripled the survival advantage with a 70% reduction in CVD mortality. This emphasizes the comprehensive cardiovascular protective effect embedded within the composite LE8 metric and validates its construction encompassing multiple modifiable health-related behaviors and biological parameters.

Intriguingly, when the population was stratified to reflect adults with cancer diagnosis histories, the LE8 score continued to demonstrate a protective trend against all-cause mortality, albeit with slightly attenuated effect sizes. Here, moderate cardiovascular health scores were associated with a 27% reduced risk of death, a significant finding affirming that optimal cardiovascular health remains critically relevant even among individuals grappling with oncologic disease. However, high LE8 scores in cancer patients did not exhibit statistically significant mortality risk reductions as clearly, indicating complex interplay between cancer pathology and cardiovascular health factors.

A noteworthy aspect of this study was the consistent protective effects observed across all eight components of the LE8 score in relation to cardiovascular mortality. This finding confirms the integrated nature of cardiovascular health determinants and advocates for multipronged interventions rather than singular focus on isolated risk factors. Each LE8 element—from diet and physical activity to blood pressure, cholesterol, glucose levels, body mass index, smoking status, and sleep health—played a vital role in enhancing cardiovascular prognosis.

The methodological approach using Cox regression modeling allowed adjustment for critical confounders, strengthening the causal inferences drawn from the associations observed. The use of restricted cubic splines further permitted the exploration of potential nonlinear relationships between LE8 score levels and mortality risks, enhancing understanding beyond binary risk categorizations and revealing dose-response dynamics.

Crucially, this study bridges a knowledge gap concerning the interplay between cardiovascular health and cancer survivorship, an increasingly pertinent arena given the rising numbers of aging cancer survivors prone to cardiovascular complications. The data advocate for integrating cardiovascular health optimization as an essential aspect of comprehensive cancer care and survivorship programs to improve longevity outcomes.

Moreover, the public health implications are profound. Given the prevalence of suboptimal cardiovascular health in the general population and the mounting burden of cancer diagnoses, strategies to improve LE8 scores at the population level could translate into reduced overall mortality and better quality of life. Health policy initiatives could prioritize cardiovascular health screening using the LE8 algorithm, lifestyle modification programs, and targeted therapeutics integration across diverse clinical settings.

This pioneering research dovetails with ongoing efforts to enhance predictive algorithms incorporating lifestyle, biological, and clinical factors to generate personalized mortality risk profiles. It reinforces the importance of holistic health metrics that capture multiple dimensions of well-being beyond traditional singular biomarker assessments, advancing precision medicine paradigms.

In conclusion, the 2025 study led by Peng et al. provides robust epidemiological evidence that the Life’s Essential 8 cardiovascular health score is a powerful tool for predicting both cardiovascular and all-cause mortality risks in adults, regardless of cancer status. These findings serve as a clarion call for clinicians, researchers, and public health authorities to embrace the LE8 paradigm to foster healthier populations and mitigate deaths linked to cardiovascular disease and potentially cancer-associated mortality.

Continued longitudinal research and intervention trials are warranted to explore causality more definitively and assess how modifications in LE8 components may translate into mortality improvements over time, particularly in vulnerable groups such as cancer survivors. As the medical community progresses toward integrated chronic disease prevention and management, the Life’s Essential 8 stands out as a beacon guiding evidence-based cardiovascular health promotion.

Subject of Research:
Cardiovascular health assessment using the American Heart Association’s Life’s Essential 8 (LE8) and its association with all-cause and cardiovascular mortality in adults with and without cancer.

Article Title:
Association of the American Heart Association’s new “Life’s Essential 8″ cardiovascular health with all-cause and cardiovascular mortality in adults with and without cancer: a retrospective cohort study.

Article References:
Peng, S., Chen, Q., Liu, Q., et al. Association of the American Heart Association’s new “Life’s Essential 8” cardiovascular health with all-cause and cardiovascular mortality in adults with and without cancer: a retrospective cohort study. BMC Cancer 25, 1706 (2025). https://doi.org/10.1186/s12885-025-14464-7

Image Credits:
Scienmag.com

DOI:
10.1186/s12885-025-14464-7 (Published 04 November 2025)

Keywords:
Cardiovascular health, Life’s Essential 8, all-cause mortality, cardiovascular mortality, cancer survivorship, NHANES, retrospective cohort study, AHA health metrics